Skip Navigation



Annals of Oncology Advance Access published online on October 11, 2005
Annals of Oncology, doi:10.1093/annonc/mdi409
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/12/1974    most recent
mdi409v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jahnke, K.
Right arrow Articles by Korfel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jahnke, K.
Right arrow Articles by Korfel, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received June 6, 2005
Revised August 2, 2005
Accepted August 4, 2005

Original article

Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma

K. Jahnke 1*, T. Wagner 2, N. E. Bechrakis 3, G. Willerding 3, S. E. Coupland 4, L. Fischer 1, E. Thiel 1, and A. Korfel 1

1 Department of Haematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
2 Department of Internal Medicine, Medical University of Lübeck, Lübeck, Germany
3 Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
4 Department of General Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin Germany

* To whom correspondence should be addressed.
K. Jahnke, E-mail: kristoph.jahnke{at}charite.de


  Abstract

Background: The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has not yet been defined. The study assesses ifosfamide (IFO) and trofosfamide (TRO) for treating IOL.

Patients and methods: We prospectively evaluated the efficacy and aqueous penetration of intravenous IFO, oral TRO and their active 4-hydroxy (4-OH) metabolites in 10 patients with IOL. Doses varied from 1500 to 2000 mg/m2/day on days 1-3 for IFO and from 150 to 400 mg/day (continuous or intermittent administration) for TRO. Four patients had newly diagnosed disease, and six had relapsed after pretreatment.

Results: All patients responded to first treatment with IFO or TRO, and both of two patients responded to re-treatment with IFO on ocular relapse. Progression-free survival from the first treatment with IFO or TRO was ≥6-18 months. In six of six patients, 4-OH metabolites were detected in the aqueous humor at a concentration of 0.32-1.56 µM immediately after IFO infusion with an aqueous/serum ratio of 0.19-0.54. 4-OH metabolites could be detected in one of three patients at a concentration of 7.2 µM 3-16 h after ingestion of TRO.

Conclusions: IFO and TRO are active in IOL. IOL patients evidence aqueous penetration of 4-OH metabolites after intravenous administration of IFO.

Keywords: aqueous; ifosfamide; intraocular lymphoma; trofosfamide.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, et al.
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
J. Clin. Oncol., June 1, 2007; 25(16): 2295 - 2305.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.